Tissue Regenix Group plc (TRX.L)

61,50 +0,50 (+0,82%) Alla chiusura: 04:11PM BST

Tissue Regenix Group plc

Phoenix Court
Unit 3 Lotherton Way
Garforth LS25 2GY
United Kingdom
44 33 0430 3052
https://www.tissueregenix.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 82

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Daniel Ray Lee	CEO & Director	496,78k	N/D	1961
Mr. David Claiborne Cocke	CFO & Executive Director	293,59k	N/D	1965
Ms. Christine Rowley	Technical & Operations Director - UK	N/D	N/D	N/D
Tina Trimble	Senior Vice President, Donor Services - U.S.	N/D	N/D	N/D
Ms. Kirsten Mary Lund	EMEA Business Director & Company Secretary	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in GBp.

Descrizione

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally. The company operates through dCELL, BioRinse, and GBM-V segments. It also provides dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductivity to stimulate and regenerate native bone growth. In addition, the company offers DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, a decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. Further, it provides OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company offers DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks to optimise membrane defects; and sports medicine products. Tissue Regenix Group plc was incorporated in 2006 and is based in Garforth, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di Tissue Regenix Group plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.